Cargando…
Low- Versus High-Dose Methylprednisolone in Adult Patients With Coronavirus Disease 2019: Less Is More
BACKGROUND: Corticosteroids use in severe coronavirus disease 2019 (COVID-19) improves survival; however, the optimal dose is not established. We aim to evaluate clinical outcomes in patients with severe COVID-19 receiving high-dose corticosteroids (HDC) versus low-dose corticosteroids (LDC). METHOD...
Autores principales: | Joshi, Seema, Smith, Zachary, Soman, Sana, Jain, Saniya, Yako, Atheel, Hojeij, Marwa, Massoud, Louis, Alsaadi, Ayman, Williams, Jonathan, Kenney, Rachel, Miller, Joseph, Alangaden, George, Ramesh, Mayur |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689728/ https://www.ncbi.nlm.nih.gov/pubmed/35024376 http://dx.doi.org/10.1093/ofid/ofab619 |
Ejemplares similares
-
497. Moderate Versus High Dose Corticosteroids in Adult Patients with Severe COVID-19: Less Is More
por: Joshi, Seema, et al.
Publicado: (2021) -
Progression to Critical Illness and Death in Patients With Breakthrough Hospitalizations
por: Suleyman, Geehan, et al.
Publicado: (2022) -
Risk Factors Associated With Hospitalization and Death in COVID-19 Breakthrough Infections
por: Suleyman, Geehan, et al.
Publicado: (2022) -
Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients
por: Birk, Navina K, et al.
Publicado: (2022) -
Spinal and Paraspinal Fungal Infections Associated With Contaminated Methylprednisolone Injections
por: Moudgal, Varsha, et al.
Publicado: (2014)